Disposition and metabolism of [14C]-galunisertib, a TGF-βRI kinase/ALK5 inhibitor, following oral administration in healthy subjects and mechanistic prediction of the effect of itraconazole on galunisertib pharmacokinetics-Reference-Cited by-同舟云学术

Disposition and metabolism of [14C]-galunisertib, a TGF-βRI kinase/ALK5 inhibitor, following oral administration in healthy subjects and mechanistic prediction of the effect of itraconazole on galunisertib pharmacokinetics

Published:2017-05-16 Issue:4 Volume:48 Page:382-399
ISSN:0049-8254
Container-title:Xenobiotica
language:en
Short-container-title:Xenobiotica

Author:

Cassidy Kenneth C.¹,Gueorguieva Ivelina²,Miles Colin²,Rehmel Jessica¹,Yi Ping¹,Ehlhardt William J.¹

Affiliation:

1. Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA and

2. Eli Lilly and Company Erl Wood, Windlesham, UK

Publisher

Informa UK Limited

Subject

Health, Toxicology and Mutagenesis,Pharmacology,Toxicology,Biochemistry,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/00498254.2017.1323137

Reference27 articles.

1. Azaro A, Baselga J, Sepúlveda JM, et al. (2012). The oral transforming growth factor-beta (TGF-β) receptor I kinase inhibitor galunisertib plus lomustine in patients with treatment-refractory malignant glioma: the first human dose study. ASCO Annual Meeting; Chicago, IL. J Clin Oncol. Abstract Number 2042.

2. Mass Balance Studies, with a Focus on Anticancer Drugs

3. Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry

4. Trabectedin (YondelisTM, formerly ET-743), a mass balance study in patients with advanced cancer

5. Determination of Human Hepatocyte Intrinsic Clearance for Slowly Metabolized Compounds: Comparison of a Primary Hepatocyte/Stromal Cell Co-culture with Plated Primary Hepatocytes and HepaRG

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IDO and TGF-β Inhibitors for the Treatment of Lung Cancer;Immunotherapy Against Lung Cancer;2024

2. Design, conduct, and interpretation of human mass balance studies and strategies for assessing metabolites-in-safety testing (MIST) in drug development;Overcoming Obstacles in Drug Discovery and Development;2023

3. Microfluidic‐Assisted Production of Gastro‐Resistant Active‐Targeted Diatomite Nanoparticles for the Local Release of Galunisertib in Metastatic Colorectal Cancer Cells;Advanced Healthcare Materials;2022-12-11

4. Integration of healthy volunteers in early phase clinical trials with immuno-oncological compounds;Frontiers in Oncology;2022-08-29

5. Synthesis and Evaluation of Chiral Rhodanine Derivatives Bearing Quinoxalinyl Imidazole Moiety as ALK5 Inhibitors;Medicinal Chemistry;2022-04